www.arbutusbio.com Open in urlscan Pro
104.198.108.226  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Arbutus Biopharma
 * About
   * Leadership
   * Board
   * Scientific Advisors
   * Culture & Careers
   * Open Opportunities
 * Science
   * HBV Assets
     * AB-729
     * AB-836
     * AB-101
     * AB-161
   * Coronavirus Assets
 * Pipeline
 * Partnering
 * Investors
   * Investor Center
   * Stock Information
   * Financial Information
   * Corporate Governance
   * Press Releases
   * Events & Presentations
   * Investor FAQ
   * Contact Us
 * Culture & Careers

 * News & Events
 * Publications
 * Patient Resources
 * Contact


BROAD PORTFOLIO INNOVATIVE ASSETS
TO HEAL A WORLD IN NEED.

We are a virology-focused biotech that is on a mission to bring our dynamic
portfolio of clinical and pre-clinical assets to the patients that need them
most.




FOCUSED ON HEALING. FOCUSED ON GROWTH.

Just like our namesake Arbutus, a healing plant native to North America, we are
leveraging our growing innovative portfolio of assets to focus our efforts on
treating and curing conditions with unmet medical need. Today, our virology
pipeline has active clinical and pre-clinical studies in the areas of Hepatitis
B virus (HBV) and pan-coronavirus.

Explore our pipeline




WE ARE ÄR-‘BYÜ-TUHS. (ARBUTUS)
HERE’S WHAT SETS US APART.

A broad and innovative virology portfolio.

We are proud of our robust internal research capabilities, which have yielded an
impressive portfolio of assets for the treatment of diverse viral diseases.

Focused on combination regimens for maximum impact.

We are committed to harnessing combination drug development to attack different
aspects of viruses and diseases and to elevate the convenience of finite
treatments.

Deep experience in drug development.

Our team includes leaders with the deep scientific and commercial expertise
needed to accelerate and strengthen our robust portfolio’s path to market.

Discover our story

HBV


COMPLEMENTARY MECHANISMS TO PURSUE AN HBV CURE.

Hepatitis B virus (HBV) therapeutic success requires a multi-faceted approach.
Our three-pronged Suppress, Reduce, Boost method harnesses multiple agents with
complementary mechanisms of action to maximize impact.

Suppress viral DNA
to stop replication.

Reduce viral antigens
to block HBsAg.

Boost and reawaken
the host’s immune response.

Learn about our progress for HBV

CORONAVIRUS


DIRECT-ACTING ANTIVIRALS TO ADVANCE PAN-CORONAVIRUS TREATMENT.

Few viruses have had a more pervasive impact around the globe than SARS-CoV-2.
We are leveraging our proven expertise in virology to develop direct-acting
antivirals that target polymerase and protease enzymes to treat COVID-19 and
other coronaviruses.

Learn about our progress for Coronaviruses




HELPFUL RESOURCES FOR YOU.

NEWS

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

Read More

EVENTS

Arbutus Biopharma Corporation 2022 Third Quarter Financial Results and Corporate
Update

Read More

PUBLICATIONS

Explore our Scientific Posters & Presentations

Read More

 * About
 * Science
 * Pipeline
 * Partnering
 * Investors
 * Culture & Careers

 * News & Events
 * Contact Us
 * Publications
 * Patient Resources
 * Terms of Use & Privacy Policy

 * LinkedIn





Transparency in Coverage

Copyright © 2022 Arbutus Biopharma, All Rights Reserved.

We use cookies on our website to give you the most relevant experience by
remembering your preferences and repeat visits. By clicking “Accept All”, you
consent to the use of ALL the cookies. However, you may visit "Cookie Settings"
to provide a controlled consent.
Cookie SettingsAccept All
Manage consent
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
These cookies ensure basic functionalities and security features of the website,
anonymously.

CookieDurationDescriptioncookielawinfo-checkbox-analytics11 monthsThis cookie is
set by GDPR Cookie Consent plugin. The cookie is used to store the user consent
for the cookies in the category "Analytics".cookielawinfo-checkbox-functional11
monthsThe cookie is set by GDPR cookie consent to record the user consent for
the cookies in the category "Functional".cookielawinfo-checkbox-necessary11
monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to
store the user consent for the cookies in the category
"Necessary".cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookie is used to store the user consent for the
cookies in the category "Other.cookielawinfo-checkbox-performance11 monthsThis
cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the
user consent for the cookies in the category
"Performance".viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie
Consent plugin and is used to store whether or not user has consented to the use
of cookies. It does not store any personal data.

Functional
Functional
Functional cookies help to perform certain functionalities like sharing the
content of the website on social media platforms, collect feedbacks, and other
third-party features.
Performance
Performance
Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.
Analytics
Analytics
Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics the number of
visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and
marketing campaigns. These cookies track visitors across websites and collect
information to provide customized ads.
Others
Others
Other uncategorized cookies are those that are being analyzed and have not been
classified into a category as yet.
SAVE & ACCEPT


 *  About
   * Leadership
   * Board
   * Scientific Advisors
   * Culture & Careers
   * Open Opportunities
 *  Science
   *  HBV Assets
     * AB-729
     * AB-836
     * AB-101
     * AB-161
   * Coronavirus Assets
 * Pipeline
 * Partnering
 *  Investors
   * Investor Center
   * Stock Information
   * Financial Information
   * Corporate Governance
   * Press Releases
   * Events & Presentations
   * Investor FAQ
   * Contact Us
 * Culture & Careers

 * News & Events
 * Publications
 * Patient Resources
 * Contact